The objective of this partnership was the establishment of an integrated primary healthcare system with conventional and traditional medicine in the Makoko/Iwaya Waterfront community.
Improve and expand routine viral load monitoring for people living with HIV in the Districts of Butha-Buthe and Mokhotlong at the Butha-Buthe government hospital Laboratory; establish sustainable HIV drug resistance testing for patients with treatment failure while taking antiretroviral therapy at Seboche St Charles Mission Hospital laboratory, Butha-Buthe District.
This partnership had as objective to improve local capacity for the management of chronic viral hepatitis B infection by developing a training partnership between Bern and Dakar University Hospitals.
The partnership between Switzerland and Peru aimed at contributing to the strengthening of Peru´s health systems capacity in providing culturally appropriate care for HIV/AIDS and other STDs for indigenous people. This was done through improved training to health workers and capacity-building of indigenous organizations.
This multi-stakeholder partnership aimed at improving and expanding routine viral load monitoring for people living with HIV in the Districts of Butha-Buthe and Mokhotlong. A further objective was to establish a sustainable HIV drug resistance testing for patients with treatment failure while taking antiretroviral therapy.
The purpose of this start-up was to assess needs and institutional capacity in terms of HIV prevention and sexual and reproductive health services within the Baptis Community of the Cogo River's Health Network. This will lay the ground for a long-term partnership between the two institutions.
The partnership assessed the prevalence of transmitted HIV‐1 drug resistance (TDR) in the chosen study sites and identified the most prevalent types of drug resistance mutations. They also assessed the potential to scale up of the HIV‐1 genotypic drug resistance test in Cameroon. Finally, they identified the major transmission routes of HIV‐1 and HIV‐1 drug resistance mutations in the study sites.